Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Queensland Health
Daiichi Sankyo
UBS
Fish and Richardson
Merck
Farmers Insurance
Dow
Cerilliant

Pharmaceutical companies with the most orphan drugs

Orphan drug exclusivity is granted to drugs addressing rare 'orphan diseases' — those affecting fewer than 200,000 Americans.

The protection granted to orphan drugs is quite strong. The FDA is barred from approving any other biologic or small-molecule drug, generic/follow-on or otherwise, treating the same orphan disease for seven years.

This chart shows the companies which have received the most orphan drug exclusivities in the past five years.

The companies with the most orphan drug approvals are:

Back to Pharmaceutical Industry Infographics

For more information try a trial or see the plans and pricing